Join
Live feed
·
PRReleasevia Quantisnow
Precigen Inc. logo

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

ByQuantisnow·Wall Street's wire, on your screen.
PGEN· Precigen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PGEN (Precigen Inc.) and more on Quantisnow.